Pqshield Inc

AccessibilityOz is a leading accessibility consultancy with offices in New York and Australia, offering expertise in digital accessibility solutions. With a focus on ensuring websites and digital content are inclusive to all users, AccessibilityOz provides services to improve accessibility compliance and user experience. Generated from their website's infomation

Consensus Systems Technologies Corp, based in New York, NY, is a DBE/MBE certified firm specializing in the application of systems engineering to Intelligent Transportation Systems (ITS). With a strong emphasis on Systems Engineering, ConSysTec's skilled staff expertly manages complex systems within the ITS realm, aiding clients in navigating project risks while complying with FHWA and FTA policies. Renowned for its work in developing regional and statewide ITS architectures, ConSysTec has contributed significantly to over 90 regions, states, and countries. The company excels in creating interoperable and multimodal ITS architectures, swiftly delivering stakeholder consensus-driven solutions that are practical and efficient. Actively engaged in shaping ITS and CV Standards, ConSysTec is a key player in the development of crucial ITS standards, including those for Connected Vehicles (CV). By participating in various Standards Development Organizations, ConSysTec ensures its involvement in shaping the future of ITS/CV standards, contributing to industry advancements and promoting adherence to data standards beyond highways. Generated from the website content

Qlucore is a New York-based company that specializes in visualization-based analysis software for research and cancer diagnostics. Their powerful and flexible solutions, such as Qlucore Omics Explorer, Qlucore Insights, and Qlucore Diagnostics, enable scientists, technicians, and physicians to easily explore, interpret, and make clinical decisions based on multi-omics data. With a team of world-renowned scientists and industry experts, Qlucore aims to accelerate, simplify, and improve precision medicine by expanding capabilities for disease subtyping, advancing research in tandem with drug development, and generating more and better results from omics data. Their intuitive and comprehensive toolset empowers scientists to understand the story that data tells, without the need for constant consultation with biostatisticians.Generated from the website